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Abstract
The key to optimising our approach in early breast cancer is to
individualise care. Each patient has a tumour with innate features
that dictate their chance of relapse and their responsiveness to
treatment. Often patients with similar clinical and pathological
tumours will have markedly different outcomes and responses to
adjuvant intervention. These differences are encoded in the tumour
genetic profile. Effective biomarkers may replace or complement
traditional clinical and histopathological markers in assessing
tumour behaviour and risk. Development of high-throughput
genomic technologies is enabling the study of gene expression
profiles of tumours. Genomic fingerprints may refine prediction of
the course of disease and response to adjuvant interventions. This
review will focus on the role of multiparameter gene expression
analyses in early breast cancer, with regards to prognosis and
prediction. The prognostic role of genomic signatures, particularly
the Mammaprint and Rotterdam signatures, is evolving. With
regard to prediction of outcome, the Oncotype Dx multigene assay
is in clinical use in tamoxifen treated patients. Extensive research
continues on predictive gene identification for specific chemo-
therapeutic agents, particularly the anthracyclines, taxanes and
alkylating agents.
Introduction
Over the past decade there have been exciting developments
in gene expression analysis [1]. Assessment of the genetic
profiles of tumours furthers our understanding of their com-
position and behaviour. These signatures are enabling
improved diagnosis, prognostic classification and more
accurate prediction of benefit from chemotherapy for individual
patients. Genetic profiles also assist pharmacogenomic
development by providing potential new targets for therapies.
Breast cancer is a prevalent disease and a leading cause of
cancer death in women. Adjuvant systemic therapy improves
disease-free survival and overall survival (OS) in some women
[2,3]. Patients with poor prognostic features benefit the most
from adjuvant therapy and identification of these high risk
women is an ongoing challenge. Individualised systemic
treatment for these women should improve outcomes.
Conversely, identification of women with a good prognosis, or
low risk of recurrent disease, may be spared the rigours and
potential complications associated with adjuvant therapy.
Traditionally, patients have been stratified according to risk of
recurrence by clinical and histopathological features. These
features have not proven adequate to identify patients who
will most benefit from adjuvant therapy. For patients and
clinicians there is a fear of under-treating in the adjuvant
setting, potentially resulting in recurrent, incurable metastatic
disease. Consequently, over-treatment in the adjuvant setting
is not uncommon.
Prognosis
Molecular identification and classification of tumours enables
important distinctions to be made between tumours that may
appear similar based on traditional clinical and histopatho-
logical systems [4]. Traditional prognostic factors include
age, tumour size, lymph node status, histological type, grade,
human epidermal growth factor receptor-2 (Her-2) status and
hormone receptor status. [5-7]. A devastating feature of any
tumour is its capacity to metastasize. It is possible that the
ability to metastasize is not a late acquisition of a cancer as
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previously thought, but an early and inherent genetic property
of breast cancer that may be detected at diagnosis of the
primary tumour.
Gene expression profiles are powerful tools. Development
and validation of these profiles are providing greater under-
standing of tumour behaviour. The clinical role for these tools
is potentially great but their specific role is still being explored
and refined.
Mammaprint
MammaPrint is a 70 gene expression profile marketed by
Agendia. The MammaPrint assay was developed based on
research initially conducted at the Netherlands Cancer
Institute, Amsterdam, andcollaborating institutions.
To identify a genetic signature strongly predictive of short
time to distant metastases van’t Veer and colleagues [8]
undertook DNA microarray analysis on primary breast
tumours of 117 young women (<55 years old) with lymph
node-negative disease. Snap frozen tissue was used to
derive RNA. Unsupervised analysis with 25,000 genes
revealed clustering of approximately 5,000 significant genes.
Supervised analysis of 78 patients with sporadic, node-
negative breast cancer revealed a 70 gene set to identify
early relapse. The poor prognosis group included 34 of the
78 patients who developed distant metastases within 5 years
of diagnosis. The poor prognosis signature comprised genes
regulating cell cycle, invasion, metastasis, signal transduction
and angiogenesis. Interestingly, there was omission of
previously identified individual genes associated with
outcome, for example, those encoding the oestrogen
receptor (ER), Her-2, and cyclin D1. This supports the power
of a collective genetic signature over individual genes. A
small validation was performed on 19 young, lymph node-
negative women, 12 of whom had developed metastases
within 5 years of original diagnosis. Of these 19, 17 were
correctly classified. Results indicate that prognosis can be
derived from primary tumour gene expression.
The same research group further validated this 70-gene
profile in 295 young women (<53 years old) with lymph
node-negative or -positive disease [9]. Sixty one of the
lymph node-negative patients were also used in the original
study; 130 patients received chemotherapy and/or
hormonal therapy. The genetic signature based on the 70-
gene profile predicted metastasis-free survival and OS.
With multivariable Cox analysis the signature was inde-
pendent of more traditionally recognised prognostic markers.
The hazard ratio for distant metastasis (HR = 5.1, 95%
confidence interval (CI) 2.9 to 9.0, p < 0.001) remained
significant, even when analysed according to lymph node
status. This independence from lymph node status was
surprising as lymph node status is traditionally recognised
as one of the strongest histopathological markers for
prognosis.
Espinosa and colleagues [10] sought to reproduce the
results of the 70-gene profile with quantitative reverse
transcriptase PCR (qRT-PCR) rather than by microarray
analysis. They divided 96 patients with node-positive or
-negative disease and a median age of 57 years into good
and poor prognosis groups. qRT-PCR reproduced the
microarray results for the 70-gene profile. Relapse-free
survival and OS differed significantly between the two
groups. For good and poor prognosis groups at 70 months,
relapse-free survival was 85% versus 62% and OS was 97%
versus 72%, respectively. From multivariate analysis only
lymph node status and gene profile were significant for OS.
Buyse and colleagues [11], through the TRANSBIG research
network [12], undertook independent validation of the 70-
gene prognostic signature for women with lymph node-
negative breast cancer. This multinational, retrospective trial
analysed 307 women, aged less than 61 years, with lymph
node-negative disease who did not receive adjuvant therapy.
Median follow-up was 13.6 years. The patients were divided
into high and low risk groups based on gene signature and
clinical risk factors. Clinical risk was assessed using
Adjuvant! Online software [13]. As predicted by the gene
signature, time to distant metastases had a HR of 2.32 (95%
CI 1.35 to 4.0) and OS had a HR of 2.79 (95% CI 1.60 to
4.87). The 70-gene microarray signature was superior to
clinicopathological risk assessment in predicting all
endpoints.
Rotterdam
Another multiparameter gene expression tool, the ‘Rotterdam
Signature’, was created at the Erasmus MC/Danail den Hoed
Cancer  Centre, Rotterdam. Of interest, this 76-gene set
shares only three genes with the aforementioned MammaPrint.
Analysis was undertaken on stored tissue of 286 patients
with lymph node-negative primary breast cancer who did not
receive any adjuvant systemic therapy [14]; median age was
52 years. From an original training set of 115 tumours, a 76-
gene signature was identified for good and poor prognosis.
This was validated in a second set of 171 patients with 93%
sensitivity and 48% specificity. The HR for distant recurrence
within 5 years was 5.67 (95% CI 2.59 to 12.4 ) and only
slightly less in a multivariate analysis (HR 5.55, 95% CI 2.46
to 12.5). After 5 years, the absolute differences in distant
metastases-free survival and OS between good and poor
signatures was 40% and 27%, respectively.
Independent multicentre validation of this tool was
undertaken by Foekens and colleagues [15]. The previously
identified 76-gene signature was applied to 180 lymph node-
negative, untreated patients. Results of this study confirmed
the signature as a strong predictive marker. The gene set
identified patients at high risk of distant metastases within
5 years of original diagnosis with a HR of 7.41 (95% CI 2.63
to 20.9), which was maintained in multivariate analysis (HR11.36, 95% CI 2.67 to 48.8). An interesting comparison of
the gene set with the 2003 St Gallen [16] and the 2001
National Institute of Health guidelines [17] was described.
Approximately 40% of patients identified as high risk by these
traditional clinicopathological risk assessments would have
been spared their adjuvant treatment using the gene
signature.
TRANSBIG assessed the 76-gene assay in the same
population of patients it used to validate the 70-gene set [18]
The results showed that the two signatures performed
similarly and were both superior to the traditional risk assess-
ment tools.
Current clinical application of microarray analysis
The results from the Mammaprint and Rotterdam signature
are encouraging. However, several criticisms and concerns
about the studies were highlighted [19]. Patient numbers in
the training and validation sets were small. The Mammaprint
study also had 61 patients overlap between their two groups.
Patient selection varied between the trials in terms of age
inclusion, lymph node status and adjuvant therapy. The trials
were retrospective and performed on frozen, stored tissue.
Only three genes were shared between the two microarray
signatures. This lack of gene overlap in the two signatures,
which were designed to assess the same risk, may reflect
different microarray platforms, different techniques and
different experimental conditions.
A large, multicentre, prospective, randomised trial is
necessary to test these microarray genomic profiles.
TRANSBIG is now undertaking such a trial using the
MammaPrint profile. This trial, MINDACT (‘Microarray for
Node Negative and 1 to 3 Positive Node Disease may Avoid
Chemotherapy’), aims to recruit 6,000 women with node-
negative early breast cancer in which patient decisions will be
madebased on a random assignment to use the MammaPrint
assay ornot [20] (Figure 1).
TRANSBIG has opted for the 70-gene signature for this
study. Earlier concerns about concordance between different
laboratories have been addressed, with TRANSBIG
satisfactorily showing concordance between laboratory
results if adherence to protocols is maintained [21]. The
focus of this trial will be on patients who have discordance
between risk assessment by the 70-gene set and traditional
clinicopathological risk assessment using Adjuvant!. Pros-
pective validation of the gene set as a prognostic tool is
imperative, but the trial design also allows for potential
predictive power of the tool for specific response to
anthracycline- or docetaxel-based chemotherapy.
Clearly, the results of this trial will be eagerly awaited to guide
the clinical use of these genomic profiles. Until these results
are available there is currently not strong enough data to
implement the gene arrays in daily practice for prognosis of
patients.
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Figure 1
Outline of the TRANSBIG MINDACT trial. Clin-path, clinical-pathological; CT, chemotherapy; HT, hormone therapy; y, year.Prognosis determination, regardless of the means of
assessment, provides information about the natural history of
a patient with early breast cancer. Prognostic tools have been
valuable in identifying patients with aggressive disease and,
as we have been deficient in clinically reliable predictive tools,
they have been used to guide adjuvant therapies. However,
the critical issue in early breast cancer is not actual
prognosis, but whether a specific intervention will significantly
improve prognosis. A patient at low risk of disease relapse -
that is, with a good prognosis - may still consider adjuvant
intervention if the relative risk reduction is significant and the
risk of treatment is low. Conversely, a patient at high risk of
relapse may have appropriate reservations about aggressive
therapy with only minimal expected relative benefit. The
critical issue is to find predictive tools to specify therapy for a
specific patient, whether it be endocrine manipulation,
chemotherapy and/or immunotherapy. As reliable predictive
clinical tools evolve, the need for prognostic markers will
diminish.
Prediction
A significant number of women are diagnosed with lymph
node-negative and hormone receptor-positive disease and
many of these women currently receive adjuvant chemo-
therapy. Only few will receive much additional benefit from
the chemotherapy over the benefit from endocrine therapy.
Also, a small group of women may not be offered
chemotherapy who will derive benefit. Ideally, molecular
signatures would be able to not only identify the women at
highest risk of recurrence, but also predict their benefit from
therapy. Molecular signatures have been examined from
women with recurrent disease and women without recurrent
disease to compare their disease profiles and benefit from
therapy. Patients with similar tumours clinically may respond
differently to treatment, in terms of response and toxicities,
likely attributable to genetic heterogeneity despite similar
phenotypes.
Oncotype Dx
The 21-gene assay Oncotype Dx is the first clinically
validated multigene assay that quantifies the likelihood of
breast cancer recurrence. It was developed specifically for
women with hormone receptor (ER)-positive and lymph node-
negative disease [22]. A real-time RT-PCR assay was
developed for RNA extracted from routine paraffin embedded
tissue; 250 candidate genes were identified from published
literature and genomic databases. Three studies involving
447 patients were used to identify any link between the 250
genes and risk of breast cancer recurrence. Twenty-one
genes associated with recurrence were identified: 16 cancer
related genes and 5 reference genes (Figure 2). This gene
panel is used to calculate a Recurrence Score (RS), a
number between 0 and 100 that correlates to a specific
likelihood of breast cancer recurrence within 10 years of
original diagnosis. Patients are then assigned as having a
low, intermediate or high risk of distant recurrence.
Once the 21-gene RT-PCR assay was defined it was
prospectively validated using a cohort from the National
Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-
14 [22]. This phase III trial compared adjuvant tamoxifen and
placebo in patients with lymph node-negative and hormone
receptor-positive primary breast cancer. Tamoxifen was
superior for reducing risk of recurrence and death [23]. Low,
intermediate and high risk groups were pre-specified as
having a RS <18, RS 18 to 31, and RS >31, respectively. Of
668 tamoxifen-treated patients, 51% were categorised as
having a low RS, 22% as having an intermediate RS and
27% as having a high RS. Ten-year Kaplan Meier estimates
for distant recurrence were 6.8%, 14.3% and 30.5%,
respectively. The RS was also predictive of overall survival
(p < 0.001).
Paik and colleagues [24] also applied the 21-gene assay in
the placebo arm of the NSABP B-14 trial to assess its
prognostic ability; 645 patients (355 placebo and 290
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Figure 2
The 21 genes identified for Oncotype Dx: 16 cancer related genes and 5
reference genes. These are used to calculate a Recurrence Score [22].
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TFRCtamoxifen treated) were analysed. The RS was significantly
associated with distant recurrence-free survival (DFS) in the
placebo arm (p < 0.05).
A second prospective validation was performed by Habel and
colleagues, who evaluated the performance of the 21-gene
assay among lymph node-negative patients who did not
receive adjuvant chemotherapy [25]. From the Northern
California Kaiser Permanente Tumour Registry of 4,964
patients, 220 cases (patients identified with death from breast
cancer as their first event) were matched to 570 controls. The
10-year risk of breast cancer death in tamoxifen treated
patients was 2.8%, 10.7% and 15.5% for those with a low,
intermediate and high RS, respectively. In patients not treated
with tamoxifen, the risks were 6.2%, 17.8% and 19.9%,
respectively. This further validated use of the 21-gene assay
with RS being strongly associated with breast cancer death.
Use of Oncotype Dx to predict benefit from chemotherapy
was shown using a cohort of patients from the NSABP B-20
trial. This phase III trial in 2,306 ER-positive, lymph node-
negative women compared adjuvant tamoxifen alone or with
chemotherapy - methotrexate and 5-fluorouracil (MF) or
cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
This trial showed a 4% absolute decrease in 10-year risk of
recurrence in the CMF and tamoxifen group [26]. Analysis of
651 patients from this trial using the 21-gene assay showed
that the benefit from chemotherapy in patients with a high RS
was dramatic, a 27.6% absolute reduction in 10-year distant
recurrent rate. Conversely, there was no clear benefit from
chemotherapy in patients with a low RS. There was
uncertainty in the intermediate group [27].
Oncotype Dx has also been analysed in lymph node-positive
patients. Albain and colleagues [28] assessed the 21-gene
assay in a cohort of postmenopausal, node-positive, ER-
positive breast cancer patients. The original phase III trial
randomized 1,158 women to adjuvant therapy with tamoxifen
alone versus cyclophosphamide, adriamycin and 5-fluo-
rouracil (CAF) with concurrent tamoxifen versus CAF with
delayed tamoxifen. CAF with delayed tamoxifen was the
superior arm for DFS and OS at 10 years [29]. A cohort of
367 women had 21-gene analysis of archived tissue, 148
from the tamoxifen alone arm and 219 from the CAF plus
tamoxifen group. The RS distribution was 40% low, 28%
intermediate and 32% high. RS was prognostic for DFS in
tamoxifen-treated patients with positive nodes (p = 0.006).
CAF with tamoxifen added no apparent benefit to tamoxifen
alone in the low RS patients, whereas there was a large
benefit for CAF in the high RS group. The study also
identified a group of patients with node-positive disease with
low RS who did not seem to benefit from the chemotherapy.
Goldstein and colleagues [30] assessed whether Oncotype
Dx could more reliably predict outcome at 5 years compared
with standard clinicopathological risk assessment (based on
an algorithm based on Adjuvant!) in a cohort from Intergroup
E2197. This phase III trial randomised 2,952 women with
node-positive (one to three nodes positive) and high risk
node-negative breast cancer to adjuvant doxorubicin/
docetaxel versus doxorubicin/cyclophosphamide. There was
no significant difference in DFS or OS at 76-month follow-up
[31]. A group of 465 patients with ER-positive disease had
21-gene analysis; 99 patients had recurrent disease. RS
predicted recurrence in node-positive and node-negative
patients (p < 0.001 for both). This prediction was more
accurate than with using traditional risk factors.
In summary, the 21-gene Oncotype Dx assay is prognostic
for hormone receptor-positive, lymph node-negative patients.
A low RS is predictive of tamoxifen benefit in hormone-
positive, node-negative cases. A high RS is predictive of
chemotherapy benefit over hormonal therapy in hormone
receptor-positive patients, regardless of lymph node status.
These trials were performed with tamoxifen. It remains to be
seen whether the tool may be predictive for other endocrine
therapy, particularly the aromatase inhibitors.
An unanswered question regarding the Oncotype Dx assay is
whether it adds more in predicting benefit than a combination
of the histopathological markers ER, progesterone receptor
(PgR), Her-2 and ki-67. Whilst Oncotype Dx has been
compared with Adjuvant!, the latter is known to assess ER
and PgR, but not Her-2 or ki-67. These histopathological
markers are limited themselves in reproducibility with current
standard methods, both within and between laboratories.
However, a combination of these markers at a high quality
laboratory, in combination with other clinical and pathological
features, may still be as good as the evolving genomic
signatures. These evolving technologies are certainly not
without extra effort and expense. The genomic signatures
have greater reproducibility and this may be their strength. A
large, prospective, randomised trial comparing a combination
of ER, PgR, Her-2 and ki67 with Oncotype Dx might be
useful to better define in which clinical situations the use of
Oncotype Dx can be recommended.
Current clinical application of 21-gene recurrence score
A potential clinical role for Oncotype Dx is in patients with
hormone receptor-positive disease with uncertain levels of
hormone sensitivity. Oncotype Dx is already commercially
available in some centres for use in newly diagnosed patients
with lymph node-negative, ER-positive primary breast cancer.
A large prospective, multicentre trial, TAILORx (Trial
Assigning Individualised Options for Treatment) is underway
for 10,000 patients with lymph node-negative, hormone
receptor-positive breast cancer [32]. Patients with an
intermediate RS (defined in this trial as RS 11 to 25) will be
randomised to chemotherapy and endocrine therapy or
endocrine therapy alone. Whilst the retrospective trials
reviewed tamoxifen-, CMF- and anthracycline-based therapies,
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chemotherapy regimen up to the treating physician.
This trial does not challenge Oncotype Dx. It presumes that
low and high RS are correct. These two groups would likely
have been identified using standard biomarkers (that is, ER,
PgR, Her-2, ki-67) and had their treatment directed accor-
dingly. However, the trial does focus on patients with
intermediate risk and results may clarify adjuvant intervention
in this group, specifically whether endocrine therapy alone is
as good as chemotherapy followed by endocrine therapy.
Prediction of specific chemotherapy benefit
Whilst gene expression signatures are providing great
advances, identification of single genes in a tumour can also
provide essential data about the tumour and its innate
behaviour. Important features of single genes include their
presence, and alterations and interactions of them with other
encoded genes. Specific genes may potentially provide
specific new targets for pharmaceutical interventions and
may also function as predictive biomarkers for response to
systemic treatment. Empirical application of chemotherapy
may be replaced by drugs specifically identified by molecular
markers as beneficial in a particular patient.
Anthracyclines
Anthracycline-based chemotherapy is commonly used in the
adjuvant setting of early breast cancer. Anthracyclines have a
survival benefit [33] but identification of the subgroup of
women who will benefit from them is a challenge. Traditional
markers have not satisfactorily identified this subgroup and
predictive biomarkers, particularly Her-2 and topoisomerase
IIa (TopoIIa), are under ongoing intensive investigation.
Her-2, topoisomerase IIA and anthracyclines
Her-2 overexpression occurs in about 30% of patients with
breast cancer and is a recognised poor prognostic marker.
Many trials have assessed Her-2 in predicting response to
anthracycline versus non-anthracycline regimens. Results
have been inconsistent. Whilst some trials have concluded a
predictive role of Her-2 overexpression for improved efficacy
of anthracycline-based adjuvant therapy [34-37], other
studies have not. Two recent meta-analyses suggest greater
benefit from the anthracycline-based therapy in women with
Her-2 overexpression for disease-free survival and overall
survival [38,39]. The mechanism underlying the interaction
between Her-2 and anthracycline therapy is not fully
understood. Her-2 may be serving as a surrogate marker for
another drug target.
A principle mechanism of action of anthracyclines is inhibition
of the TopoIIa enzyme, which is a key enzyme in DNA
replication.  In vitro and  in vivo studies suggest greater
anthracycline sensitivity in TopoIIa overexpression [40,41].
Conversely, suppression of TopoIIa produces resistance to
anthracyclines [41]. Amplification of TopoIIa results in over-
production of the TopoIIa protein and this increase in drug
target may account for improved drug efficacy. Contrasting
data confuse this issue, however, as TopoIIa deletions have
also been associated with benefit from anthracycline-based
therapy [42].
Her-2 and TopoIIa co-inhabit chromosome 17. TopoIIA
amplification occurs in 40% of Her-2 amplified breast
cancers, whilst TopoIIa gene aberration is rarely detected in
Her-2 non-amplified breast cancers [40]. Co-amplification of
Her-2 and TopoIIa may predict anthracycline benefit [36,37].
Current data suggest a benefit for Her-2-overexpressing
patients from an anthracycline versus non-anthracycline
regimen. Further results are awaited specifically addressing
the issues of the predictive role of Her-2 and TopoIIA co-
amplification, TopoIIa amplification as an independent
predictive marker, the effect of co-administration of anthra-
cyclines with trastuzumab in Her-2 amplified patients, and
clinically feasible TopoIIA measurements. TopoIIa measure-
ment is an interesting evolving area of research. Regulation of
the TopoIIa protein is complex and multifactorial (Figure 3). It
may be that identification, quantification and intracellular
localisation of the TopoIIa protein may be more clinically
relevant than quantification of the TopoIIa gene [43].
Taxanes
Taxanes cause apoptosis by binding to the interior surface of
the beta-tubulin subunit of microtubules and disrupting cell
architecture.
Her-2 and taxanes
Four trials in early breast cancer have retrospectively
assessed Her-2 as a predictive biomarker for response to
taxane therapy, one of these in the neoadjuvant setting [44-
47]. The CALGB 9344 trial compared the addition of
paclitaxel to anthracycline-based chemotherapy with anthra-
cycline-based chemotherapy alone [44]. It showed a
statistically significant improvement in DFS and OS with
addition of paclitaxel only in Her-2-overexpressing disease.
There was no taxane benefit seen in the Her-2-negative
group. A meta-analysis of the three adjuvant trials suggested
that both Her-2 amplified and Her-2 non-amplified patients
benefit from the addition of the taxane, with greater benefit in
the Her-2 amplified group [38].
Protein tau and taxanes
Microtubule-associated protein tau promotes microtubule
assembly and stabilises microtubules. Gene expression
analysis in the neoadjuvant setting with paclitaxel has
identified low expression of tau with increased chemo-
sensitivity and increased pathological complete response
[48]. This negative correlation was validated using immuno-
histochemistry on tissue arrays to assess tau. Subsequent
elegant in vitro work by the same group revealed that pre-
incubation of tubulin with tau resulted in reduced taxane
Breast Cancer Research    Vol 11 No 2 Oakman et al.
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binding. Low tau expression may become a predictive clinical
biomarker for taxane sensitivity.
Tau expression also closely correlates with ER expression
and may predict endocrine sensitivity in ER-positive breast
cancers [49,50]. Potentially high tau levels may predict ER-
positive tumours with increased sensitivity to endocrine
therapy, whereas low tau levels may distinguish ER-positive
tumours more chemosensitive to taxane therapy [50].
p53 and taxanes
p53 is a critical tumour suppressor playing an integral role in
cellular apoptosis and regulation of normal cell growth. Wild-
type p53 may undergo amplification, deletion or mutation. A
meta-analysis reviewing the link between p53 and breast
cancer revealed a poorer outcome for DFS and OS with a
p53 alteration [51]. A large study using gene sequencing and
specific mutation detection reported p53 as an independent
negative prognostic marker in breast cancer [52].
The role of p53 as a predictive marker is not clear. Some
studies have not shown any clear correlation between p53
alterations and clinical or pathological clinical response with
taxanes [53,54]. Other in vitro and  in vivo studies have
confirmed taxane response in the presence of p53 mutation,
supporting the hypothesis of p53-independent mechanisms
of action for the taxanes [55,56]. This is in contrast to
anthracyclines, whose DNA damaging effects mediate apop-
tosis via p53-dependent pathways and, as such, are depen-
dent on normal p53.
The complexity of p53 renders the detection of clinically
important p53 alterations an ongoing challenge. Immuno-
histochemistry is associated with misclassification, detecting
both wild-type and mutated p53. Identification of specific
genetic mutations is expensive and not widely available.
‘Functional’ inactivation, which is the key concern with p53,
may occur at many levels and with cross-talk between many
pathways. Inactivation may be best assessed not by single
gene analysis, but by a p53 multigene signature. Interestingly,
some p53 wild-type tumours have been shown to express the
mutant p53 signature and behave aggressively [57]. Genetic
polymorphisms may also impact on p53 activity and may
need to be incorporated into clinical predictive tools [58].
DNA damaging agents
Alkylating agents, namely cyclophosphamide, and platinum
derivatives, carboplatin and cisplatin, inhibit cell growth and
induce cell death by damaging DNA, particularly by intra- and
inter-DNA strand binding. Cyclophosphamide is frequently
used in the adjuvant treatment of breast cancer, whilst the
role of platinum derivatives is not yet clearly defined.
Hereditary breast cancer accounts for 5% to 10% of all
breast cancer cases. BRCA mutations account for 24% to
40% of hereditary breast cancers. Women with a BRCA1
mutation have a 56% to 85% lifetime risk of developing
breast cancer [59]. The normal BRCA1 gene, on chromo-
some 17, encodes DNA repair proteins required for main-
tenance of normal DNA genomic integrity. BRCA1 mutation
prevents DNA repair. In the absence of DNA repair, DNA
damaging agents exert greater effect. Certainly, preclinical
and clinical studies reveal hypersensitivity of BRCA1-
associated breast cancer to DNA damaging agents [60-62].
The clinical neoadjuvant studies were small but confirmed
increased complete clinical response in BRCA1 mutated
patients, compared with BRCA2 and sporadic cases.
Recent molecular classification of breast cancer has defined
luminal-like and basal-like tumours [63], and there is evolving
evidence of a strong link between BRCA1 deficiency and the
basal phenotype. The basal ‘triple negative’ tumours are ER-
negative, PgR-negative and Her-2-negative, and also positive
for epidermal growth factor receptor and basal cytokeratins.
They are typically high grade, aggressive tumours with a poor
prognosis. Analyses have shown that basal tumours are
similar to BRCA1 germline mutated tumours in clinical
course, immunohistochemistry and genetic signature [64].
Whilst somatic BRCA1 mutations are uncommon in sporadic
breast cancer, there are non-mutational mechanisms causing
BRCA1 dysfunction. Down-regulation of BRCA1 mRNA and
protein expression may be mediated by acquired methylation
of the BRCA1 promotor or upstream pathway regulation
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Page 7 of 11
(page number not for citation purposes)
Figure 3
Multifactorial regulation of topoisomerase IIa (TopoIIa). TopoIIa gene
transcription is under control of gene signals and proliferative signals.
Redox-sensitive protein complexes regulate mRNA half-life. Variable
mRNA splicing produces protein isoforms: the cytoplasmic form is
inactive, the nuclear form is active. Nuclear receptors regulate transport
of these isoforms depending on the cell proliferative phase [43].malfunction [59]. Like the BRCA1 tumours, there are small,
retrospective reviews of basal tumours being hypersensitive
to DNA damaging chemotherapy [65,66].
BRCA1 and the basal phenotype may be valuable predictive
biomarkers of response to DNA damaging agents, but further
exploration in larger prospective clinical trials is required.
Future directions
Traditional and genetic markers offer prognosis and possibly
predict treatment response based on the characteristics or
signatures of the primary tumour. Another approach is to
identify and quantify micrometastatic disease postoperatively
and correlate residual disease with outcome and benefit from
treatment. In the neoadjuvant and metastatic settings, the
bulk of disease and response to therapy may be gauged by
measurable disease, clinically or radiologically, or with the aid
of surrogate tumour markers or reported symptoms. In the
adjuvant setting this is not possible. Recognition of patients
with aggressive primary disease and measurable micrometa-
static disease may guide future adjuvant interventions. Tools
to assess residual disease include identification of micro-
metastases in bone marrow and blood, and possibly
proteomic or metabolomic profiles
Circulating tumour cells
Circulating tumour cells (CTCs) may be detected with high
sensitivity and specificity using immunomagnetic separation
[67] or microchip technology [68]. The ability to isolate,
quantify and molecularly categorise CTCs is a tremendous
challenge. The significance of these cells is yet to be clearly
defined. The presence of these cells may not necessarily
correlate with future relapse.
CTC profiles have been compared with the profiles of their
primary tumour. Using the gene expression of the primary
tumour to determine adjuvant therapy assumes concordance
between the primary tumour and micrometastatic deposits.
However, there is evidence that genetic alteration between
the primary tumour and CTCs may alter both prognosis and
therapy options; for example, a Her-2-negative primary
breast cancer based on immunohistochemistry and
fluorescence in situ hybridisation may in fact release CTCs
that are positive for Her-2 [69]. This may worsen the
prognosis but opens the therapeutic window for Her-2
directed therapy
In metastatic breast cancer the number of circulating tumour
cells has been shown to be an independent predictor of
progression-free survival and OS [70]. In the adjuvant setting
the role of CTCs is undergoing intensive research. The
significance of the presence, quantity and rate of post-
operative clearance of CTCs, as well as response of CTCs
during adjuvant therapy and appropriate reactions to these
responses, are being explored and will hopefully be defined
to incorporate CTCs into optimising clinical practice.
Proteomics and metabolomics
A multitude of complex variables impact on the interaction
between a tumour and its host: there are alterations that may
occur at the RNA, protein and/or metabolite level; there is the
host immune response to the tumour; and host handling of
particular chemotherapeutics may dictate dosing, scheduling
and predictive benefit for that individual. These issues are not
addressed by analyses of the genome, but are being
incorporated into analyses in proteomics and metabolomics.
These rapidly developing fields seek to further personalise
our approach in management of early breast cancer by
analysing both tumour and host.
Proteomics identifies proteins expressed in the body,
particularly defining sets of proteins expressed at a certain
time under specified conditions [71]. Metabolomics is a new
field of research aiming to analyse complete biological
systems. This high throughput study of vast quantities of
small molecules/metabolites in simple biofluids aims to
provide a ‘fingerprint’ of metabolic processes and metabolic
responses to pathophysiological and pharmaceutical inter-
vention [72]. Proteomic and metabolomic analyses may
enhance screening, diagnosis and targeted drug therapy
discovery, and may also define surrogate markers for
prognosis, response and treatment toxicity [73].
Conclusion
Identification of specific single genes and gene expression
signatures is refining our approach in early breast cancer.
Such analyses are leading the way in individualisation of
prognosis and prediction. This shift in approach from
traditional clinical and histopathological risk assessment,
which provides estimates of outcomes from disease and
interventions for a similar population of patients, to specific
tumour assessment in a specific patient with a genetic basis
for prognosis and treatment decisions is exciting. Whilst
some of the early data are encouraging, much of the research
to date is inconclusive or conflicting, and often from small
retrospective trials using archived tissue. Large prospectively
designed and well powered clinical trials will help to specify
definitive roles for these new diagnostic tools in daily clinical
practice.
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